a multicenter total therapy strategy for de novo adul Philadelphia chromosome positive acute lymphoblastic leukemia patients.

Research output: Contribution to journalArticle

Abstract

The GIMEMA LAL1509 protocol, designed for adult (≥18-60 years) de novo Ph+ acute lymphoblastic leukemia patients, was based on a dasatinib plus steroids induction - with central nervous system prophylaxis - followed by dasatinib alone in patients in complete molecular response or chemotherapy and/or allogeneic transplantation in patients not reaching a complete molecular response. Sixty patients (median age 41.9 years) were enrolled: 33 were p190+, 18 p210+ and 9 p190/p210+. At the end of induction (day +85), 58 patients (97%) achieved a complete hematologic remission. No deaths in induction were recorded. Eleven patients (18.3%) obtained a complete molecular response. Among non-complete molecular responders (n=47), 22 underwent an allogeneic transplant. Seventeen hematologic relapses occurred (median 7 months, range 3-40.1), 13 during consolidation and 4 post-transplant. ABL1 mutations (5 T315I, 3 V299L, 1 E281K and 1 G254E) were found in 10/13 relapsed cases. With a median follow-up of 57.4 months (range: 4.2-75.6), overall survival and disease-free survival are 56.3% and 47.2%. A better diseasefree survival was observed in patients who obtained a molecular response at day +85 compared to
Original languageEnglish
Pages (from-to)1-1
Number of pages1
JournalHaematologica
Publication statusPublished - 2021

Keywords

  • a multicenter total therapy strategy for de novo adul Philadelphia chromosome positive acute lymphoblastic leukemia patients.

Fingerprint Dive into the research topics of 'a multicenter total therapy strategy for de novo adul Philadelphia chromosome positive acute lymphoblastic leukemia patients.'. Together they form a unique fingerprint.

Cite this